Global Bone Metastasis Therapeutics Market Size, Status and Forecast 2019-2025

Description:
Bone metastasis is the third most common condition in metastatic cancers and occurs in 60-65% of patients with metastatic cancers. The spine is the most common site of bone metastasis. Other common sites include ribs, skull, pelvis (hip bone), femur (leg bone) and humerus (arm bone). Bone metastatic cancers are rarely able to be cured, and treatment of bone metastasis involves medications to shrink, stop or slow down the growth of the tumor. Treatment options available for bone metastasis are symptomatic treatments which are meant for pain control, treatment, and prevention of fractures, improvement in functional disability, etc. Randomized trials on metastatic patients by UBM Medica, LLC showed that 45-75% patients develop functional disability every 3-4 months, 10-15% patients develop hypercalcemia and 10-20% patients develop long bone fractures. Treatment of bone metastasis is the interdisciplinary field involving pain management, orthopedics, and other medical specialties. Primary factors driving the growth of bone metastasis therapeutics market are the global increase in cancer prevalence and delayed diagnosis of cancer in low-income countries. According to University of Texas Southwestern Medical Center Dallas, over 600,000 of bone metastasis are diagnosed in the U.S. every year. Rapid innovation in the field of personalized medicine and identification of new therapeutic targets for bone metastasis presents a huge opportunity to manufacturers of targeted therapy agents. A large number of treatment methods are still under investigation. However, heterogeneous nature of cancer and high development cost of neoplastic agents are the factors limiting the growth of global bone metastasis therapeutics market.

In 2018, the global Bone Metastasis Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Bone Metastasis Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bone Metastasis Therapeutics development in United States, Europe and China.

The key players covered in this study
- F. Hoffmann-La Roche
- Bayer
- Merck
- Pfizer
- Novartis
- Amgen
- Pharmalucence
- Fresenius Kabi
- Omega Laboratories
- Eli Lilly

Market segment by Type, the product can be split into
- Drug Treatment
- Tumor Ablation Therapy
- Surgery

Market segment by Application, split into
- Hospitals
- Cancer Rehabilitation Centers
- Specialty Clinics
- Ambulatory Surgical Centers

Market segment by Regions/Countries, this report covers
- United States
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America

The study objectives of this report are:
- To analyze global Bone Metastasis Therapeutics status, future forecast, growth opportunity, key market and key players.
- To present the Bone Metastasis Therapeutics development in United States, Europe and China.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.

In this study, the years considered to estimate the market size of Bone Metastasis Therapeutics are as follows:
- History Year: 2014-2018
- Base Year: 2018
- Estimated Year: 2019
- Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1 Report Overview

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
  1.4.1 Global Bone Metastasis Therapeutics Market Size Growth Rate by Type (2014-2025)
  1.4.2 Drug Treatment
  1.4.3 Tumor Ablation Therapy
  1.4.4 Surgery
1.5 Market by Application
  1.5.1 Global Bone Metastasis Therapeutics Market Share by Application (2014-2025)
  1.5.2 Hospitals
  1.5.3 Cancer Rehabilitation Centers
  1.5.4 Specialty Clinics
  1.5.5 Ambulatory Surgical Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends

2.1 Bone Metastasis Therapeutics Market Size
2.2 Bone Metastasis Therapeutics Growth Trends by Regions
  2.2.1 Bone Metastasis Therapeutics Market Size by Regions (2014-2025)
  2.2.2 Bone Metastasis Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Opportunities

3 Market Share by Key Players

3.1 Bone Metastasis Therapeutics Market Size by Manufacturers
  3.1.1 Global Bone Metastasis Therapeutics Revenue by Manufacturers (2014-2019)
  3.1.3 Global Bone Metastasis Therapeutics Market Concentration Ratio (CR5 and HHI)
  3.2 Bone Metastasis Therapeutics Key Players Head office and Area Served
  3.3 Key Players Bone Metastasis Therapeutics Product/Solution/Service
  3.4 Date of Enter into Bone Metastasis Therapeutics Market
  3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

4.1 Global Bone Metastasis Therapeutics Market Size by Type (2014-2019)

5 United States

5.2 Bone Metastasis Therapeutics Key Players in United States
5.3 United States Bone Metastasis Therapeutics Market Size by Type
5.4 United States Bone Metastasis Therapeutics Market Size by Application

6 Europe

6.2 Bone Metastasis Therapeutics Key Players in Europe
6.3 Europe Bone Metastasis Therapeutics Market Size by Type
6.4 Europe Bone Metastasis Therapeutics Market Size by Application

7 China

7.2 Bone Metastasis Therapeutics Key Players in China
7.3 China Bone Metastasis Therapeutics Market Size by Type
7.4 China Bone Metastasis Therapeutics Market Size by Application

8 Japan

8.2 Bone Metastasis Therapeutics Key Players in Japan
8.3 Japan Bone Metastasis Therapeutics Market Size by Type
8.4 Japan Bone Metastasis Therapeutics Market Size by Application

9 Southeast Asia

9.1 Southeast Asia Bone Metastasis Therapeutics Market Size (2014-2019)
9.2 Bone Metastasis Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Bone Metastasis Therapeutics Market Size by Type
9.4 Southeast Asia Bone Metastasis Therapeutics Market Size by Application

10 India

10.1 India Bone Metastasis Therapeutics Market Size (2014-2019)
10.2 Bone Metastasis Therapeutics Key Players in India
10.3 India Bone Metastasis Therapeutics Market Size by Type
10.4 India Bone Metastasis Therapeutics Market Size by Application

11 Central & South America

11.1 Central & South America Bone Metastasis Therapeutics Market Size (2014-2019)
11.2 Bone Metastasis Therapeutics Key Players in Central & South America
11.3 Central & South America Bone Metastasis Therapeutics Market Size by Type
11.4 Central & South America Bone Metastasis Therapeutics Market Size by Application

12 International Players Profiles

12.1 F. Hoffmann-La Roche
12.1.1 F. Hoffmann-La Roche Company Details
12.1.2 Company Description and Business Overview
12.1.3 Bone Metastasis Therapeutics Introduction
12.1.4 F. Hoffmann-La Roche Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.1.5 F. Hoffmann-La Roche Recent Development

12.2 Bayer
12.2.1 Bayer Company Details
12.2.2 Company Description and Business Overview
12.2.3 Bone Metastasis Therapeutics Introduction
12.2.4 Bayer Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.2.5 Bayer Recent Development

12.3 Merck
12.3.1 Merck Company Details
12.3.2 Company Description and Business Overview
12.3.3 Bone Metastasis Therapeutics Introduction
12.3.4 Merck Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.3.5 Merck Recent Development

12.4 Pfizer
12.4.1 Pfizer Company Details
12.4.2 Company Description and Business Overview
12.4.3 Bone Metastasis Therapeutics Introduction
12.4.4 Pfizer Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.4.5 Pfizer Recent Development

12.5 Novartis
12.5.1 Novartis Company Details
12.5.2 Company Description and Business Overview
12.5.3 Bone Metastasis Therapeutics Introduction
12.5.4 Novartis Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.5.5 Novartis Recent Development

12.6 Amgen
12.6.1 Amgen Company Details
12.6.2 Company Description and Business Overview
12.6.3 Bone Metastasis Therapeutics Introduction
12.6.4 Amgen Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.6.5 Amgen Recent Development

12.7 Pharmalucence
12.7.1 Pharmalucence Company Details
12.7.2 Company Description and Business Overview
12.7.3 Bone Metastasis Therapeutics Introduction
12.7.4 Pharmalucence Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.7.5 Pharmalucence Recent Development

12.8 Fresenius Kabi
12.8.1 Fresenius Kabi Company Details
12.8.2 Company Description and Business Overview
12.8.3 Bone Metastasis Therapeutics Introduction
12.8.5 Fresenius Kabi Recent Development

12.9 Omega Laboratories
12.9.1 Omega Laboratories Company Details
12.9.2 Company Description and Business Overview
12.9.3 Bone Metastasis Therapeutics Introduction
12.9.4 Omega Laboratories Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.9.5 Omega Laboratories Recent Development

12.10 Eli Lilly
12.10.1 Eli Lilly Company Details
12.10.2 Company Description and Business Overview
12.10.3 Bone Metastasis Therapeutics Introduction
12.10.4 Eli Lilly Revenue in Bone Metastasis Therapeutics Business (2014-2019)
12.10.5 Eli Lilly Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer